Results from our content library
AI-Powered Search
Sign in to search for any topic in our content library — get answers, related past year questions, and practice MCQs on the topic.
Sign in to searchQdenga Dengue Vaccine Approval
The recent approval of the dengue vaccine Qdenga (TAK-003) by India’s Subject Expert Committee under the Drugs Controller General of India (DCGI) marks a significant advancement in combating dengue, a major public health concern. Developed by the Japanese pharmaceutical company Takeda, Qdenga is a tetravalent, live-attenuated vaccine designed to protect against all four dengue virus serotypes (DENV-1 to DENV-4).
Historically, dengue control in India has relied primarily on vector management and symptomatic treatment, as no widely accessible and universally safe vaccine was available. Earlier vaccines like Dengvaxia had limitations, particularly requiring pre-screening for prior infection, which restricted widespread use. Qdenga overcomes this barrier by not requiring pre-vaccination screening, making it more suitable for large-scale immunisation.
Sign up free to read the full article
Free accounts include 5 articles every month across current affairs, state notes, subject notes and more — upgrade anytime for unlimited access.
Qdenga (TAK-003) dengue vaccine approved by India's DCGI in April 2026. Tetravalent live-attenuated vaccine protects against all 4 dengue serotypes without pre-screening, advancing dengue prevention strategy.
Keywords